PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

Journal of Clinical Oncology

Volumn 27, Issue 9, 2009, Pages 1477-1484

  Ogino, Shuji ^a   Nosho, Katsuhiko ^a   Kirkner, Gregory J ^a   Shima, Kaori ^a   Irahara, Natsumi ^a   Kure, Shoko ^a   Chan, Andrew T ^a   Engelman, Jeffrey A ^a   Kraft, Peter ^a   Cantley, Lewis C ^a   Giovannucci, Edward L ^a   Fuchs, Charles S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B; PROTEIN P53; B RAF KINASE; BRAF PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BRAF GENE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COHORT ANALYSIS; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; CPG ISLAND; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PHENOTYPE; PIK3CA GENE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PYROSEQUENCING; RISK FACTOR; WILD TYPE; COLON TUMOR; ENZYMOLOGY; GENETICS; MUTATION; ONCOGENE RAS; PATHOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; COLONIC NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MALE; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 63049111794     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.6544     Document Type: Article

References (44)

1. Manning BD, Cantley LC: AKT/PKB signaling: Navigating downstream. Cell 129:1261-1274, 2007
2. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619, 2006
3. Samuels Y, Velculescu VE: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3:1221-1224, 2004
4. Tabernero J, Rojo F, Calvo E, et al: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008
5. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004
6. Velho S, Oliveira C, Ferreira A, et al: The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41:1649-1654, 2005
7. Benvenuti S, Frattini M, Arena S, et al: PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 29:284-288, 2008
8. Barault L, Veyries N, Jooste V, et al: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122:2255-2259, 2008
9. Miyaki M, Iijima T, Yamaguchi T, et al: Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 121:1627-1630, 2007
10. Ollikainen M, Gylling A, Puputti M, et al: Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 121:915-920, 2007
11. Kato S, Iida S, Higuchi T, et al: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121:1771-1778, 2007
12. Abubaker J, Bavi P, Al-Harbi S, et al: Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 27:3539-3545, 2008
13. Nosho K, Kawasaki T, Ohnishi M, et al: PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia 10:534-541, 2008
14. Colditz GA, Hankinson SE: The Nurses' Health Study: Lifestyle and health among women. Nat Rev Cancer 5:388-396, 2005
15. Chan AT, Ogino S, Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142, 2007
16. Rimm EB, Stampfer MJ, Colditz GA, et al: Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1:466-473, 1990
17. Hamilton SR, Vogelstein B, Kudo S: Carcinoma of the colon and rectum, in Aaltonen LA, Hamilton SR (eds): Pathology and Genetics of Tumours of the Digestive System: World Health Organization Classification of Tumours. Lyon, France, IARC Press, 2000
18. Stampfer MJ, Willett WC, Speizer FE, et al: Test of the National Death Index. Am J Epidemiol 119:837-839, 1984
19. Ogino S, Kawasaki T, Brahmandam M, et al: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7:413-421, 2005
20. Ogino S, Kawasaki T, Kirkner GJ, et al: CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: Possible associations with male sex and KRAS mutations. J Mol Diagn 8:582-588, 2006
21. Ogino S, Kawasaki T, Brahmandam M, et al: Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8:209-217, 2006
22. Ogino S, Cantor M, Kawasaki T, et al: CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55:1000-1006, 2006
23. Ogino S, Kawasaki T, Kirkner GJ, et al: Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9:305-314, 2007
24. Weisenberger DJ, Siegmund KD, Campan M, et al: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787-793, 2006
25. Ogino S, Kawasaki T, Nosho K, et al: LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG methylator phenotype in colorectal cancer. Int J Cancer 122:2767-2773, 2008
26. Yang AS, Estecio MR, Doshi K, et al: A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 32:e38, 2004
27. Estécio MR, Gharibyan V, Shen L, et al: LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE 2:e399, 2007
28. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
29. Ogino S, Kawasaki T, Kirkner GJ, et al: Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 20:15-22, 2007
30. Itoh N, Semba S, Ito M, et al: Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94:3127-3134, 2002
31. Abdul-Ghani R, Serra V, Gyorffy B, et al: The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25:1743-1752, 2006
32. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
33. Svrcek M, El-Bchiri J, Chalastanis A, et al: Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J Clin Oncol 25:4231-4238, 2007
34. Scartozzi M, Bearzi I, Pierantoni C, et al: Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 25:3930-3935, 2007
35. Sartore-Bianchi A, Moroni M, Veronese S, et al: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238-3245, 2007
36. Kim GP, Colangelo LH, Wieand HS, et al: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25:767-772, 2007
37. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
38. Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113-130, 2007
39. Ogino S, Goel A: Molecular classification and correlates in colorectal cancer. J Mol Diagn 10:13-27, 2008
40. Ikenoue T, Kanai F, Hikiba Y, et al: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65:4562-4567, 2005
41. Vallböhmer D, Zhang W, Gordon M, et al: Molecular determinants of cetuximab efficacy. J Clin Oncol 23:3536-3544, 2005
42. Lièvre A, Bachet J-B, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006
43. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648, 2007
44. Meyerhardt JA, Giovannucci EL, Holmes MD, et al: Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 24:3527-3534, 2006